Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | BTK | Q06187 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467769 | 1.00 | CA1 (0.71) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL3487968 | 1.00 | CA1 (0.71) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL30175163 | 0.96 | CA1 (0.66) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL5556389 | 0.96 | CA1 (0.66) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL4042455 | 0.91 | CTSK (0.61) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL2049277 | 0.91 | CTSK (0.61) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL4044287 | 0.91 | CTSK (0.61) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL17545919 | 0.88 | CA1 (0.71) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL3619298 | 0.88 | CA1 (0.60) | CA1CA2BTKCTSKHSD11B1 | |
| SCHEMBL1159171 | 0.88 | CA1 (0.71) | CA1CA2BTKCTSKHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | CA1 2505/4885CA2 1343/4885BTK 2479/4885 |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | CA1 3416/4885CA2 912/4885BTK 777/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | CA1 804/4885CA2 168/4885BTK 2111/4885 |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | PPARD, SLC5A2, PPARG | CA1 4628/4885CA2 1880/4885BTK 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.